MA66371B1 - Dérivés de s-alaninate substitués - Google Patents
Dérivés de s-alaninate substituésInfo
- Publication number
- MA66371B1 MA66371B1 MA66371A MA66371A MA66371B1 MA 66371 B1 MA66371 B1 MA 66371B1 MA 66371 A MA66371 A MA 66371A MA 66371 A MA66371 A MA 66371A MA 66371 B1 MA66371 B1 MA 66371B1
- Authority
- MA
- Morocco
- Prior art keywords
- alaninate
- derivatives
- substituted
- preparation
- thrombotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des dérivés de S-alaninate substitués et des procédés pour leur préparation, et également leur utilisation pour la préparation de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier de troubles vasculaires, de préférence de troubles thrombotiques ou thromboemboliques et/ou de complications thrombotiques ou thromboemboliques.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21194781 | 2021-09-03 | ||
| EP22769666.3A EP4396183B1 (fr) | 2021-09-03 | 2022-08-29 | Dérivés de s-alaninate substitués |
| PCT/EP2022/073889 WO2023031083A1 (fr) | 2021-09-03 | 2022-08-29 | Dérivés de s-alaninate substitués |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA66371B1 true MA66371B1 (fr) | 2025-12-31 |
Family
ID=77640441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA66371A MA66371B1 (fr) | 2021-09-03 | 2022-08-29 | Dérivés de s-alaninate substitués |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20250002483A1 (fr) |
| EP (1) | EP4396183B1 (fr) |
| JP (1) | JP7546172B2 (fr) |
| KR (1) | KR20240055043A (fr) |
| CN (1) | CN117916236A (fr) |
| AR (1) | AR126980A1 (fr) |
| AU (1) | AU2022338082A1 (fr) |
| CA (1) | CA3230721A1 (fr) |
| CL (1) | CL2024000638A1 (fr) |
| CO (1) | CO2024002668A2 (fr) |
| CR (1) | CR20240114A (fr) |
| DK (1) | DK4396183T3 (fr) |
| DO (1) | DOP2024000024A (fr) |
| EC (1) | ECSP24024658A (fr) |
| ES (1) | ES3055022T3 (fr) |
| FI (1) | FI4396183T3 (fr) |
| GE (2) | GEAP202416491A (fr) |
| HR (1) | HRP20251414T1 (fr) |
| IL (1) | IL310777A (fr) |
| JO (1) | JOP20240043A1 (fr) |
| LT (1) | LT4396183T (fr) |
| MA (1) | MA66371B1 (fr) |
| MX (1) | MX2024002750A (fr) |
| PE (1) | PE20240798A1 (fr) |
| PL (1) | PL4396183T3 (fr) |
| PT (1) | PT4396183T (fr) |
| RS (1) | RS67431B1 (fr) |
| SI (1) | SI4396183T1 (fr) |
| TW (1) | TW202320754A (fr) |
| WO (1) | WO2023031083A1 (fr) |
| ZA (1) | ZA202402553B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4669644A1 (fr) * | 2023-02-21 | 2025-12-31 | Bayer Aktiengesellschaft | Dérivés de s-alaninate substitués |
| WO2025237307A1 (fr) * | 2024-05-14 | 2025-11-20 | 苏州康宁杰瑞生物科技有限公司 | Inhibiteur du facteur de coagulation sanguine fxi/fxia pour le traitement de l'hypertension pulmonaire et/ou de l'hypertension |
| CN119366487A (zh) * | 2024-10-30 | 2025-01-28 | 健帆生物科技集团股份有限公司 | 一种用于血液灌流器对内毒素吸附性能的评价方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0042675A1 (fr) | 1980-06-20 | 1981-12-30 | Norton Company | Procédé pour fixer une meule sur un arbre |
| CN102015675B (zh) * | 2008-02-21 | 2014-07-02 | 赛诺菲 | 作为凝血因子Xa和凝血酶的抑制剂的氯噻吩-酰胺 |
| US9637479B2 (en) | 2013-04-26 | 2017-05-02 | Sanofi | Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide |
-
2022
- 2022-03-29 US US18/688,014 patent/US20250002483A1/en active Pending
- 2022-08-29 EP EP22769666.3A patent/EP4396183B1/fr active Active
- 2022-08-29 IL IL310777A patent/IL310777A/en unknown
- 2022-08-29 RS RS20251161A patent/RS67431B1/sr unknown
- 2022-08-29 PT PT227696663T patent/PT4396183T/pt unknown
- 2022-08-29 FI FIEP22769666.3T patent/FI4396183T3/fi active
- 2022-08-29 KR KR1020247010671A patent/KR20240055043A/ko active Pending
- 2022-08-29 CR CR20240114A patent/CR20240114A/es unknown
- 2022-08-29 JP JP2023550005A patent/JP7546172B2/ja active Active
- 2022-08-29 SI SI202230208T patent/SI4396183T1/sl unknown
- 2022-08-29 CA CA3230721A patent/CA3230721A1/fr active Pending
- 2022-08-29 WO PCT/EP2022/073889 patent/WO2023031083A1/fr not_active Ceased
- 2022-08-29 AU AU2022338082A patent/AU2022338082A1/en active Pending
- 2022-08-29 GE GEAP202416491A patent/GEAP202416491A/en unknown
- 2022-08-29 PL PL22769666.3T patent/PL4396183T3/pl unknown
- 2022-08-29 DK DK22769666.3T patent/DK4396183T3/da active
- 2022-08-29 ES ES22769666T patent/ES3055022T3/es active Active
- 2022-08-29 CN CN202280059583.8A patent/CN117916236A/zh active Pending
- 2022-08-29 GE GEAP202216491A patent/GEP20257776B/en unknown
- 2022-08-29 MX MX2024002750A patent/MX2024002750A/es unknown
- 2022-08-29 MA MA66371A patent/MA66371B1/fr unknown
- 2022-08-29 HR HRP20251414TT patent/HRP20251414T1/hr unknown
- 2022-08-29 LT LTEPPCT/EP2022/073889T patent/LT4396183T/lt unknown
- 2022-08-29 PE PE2024000363A patent/PE20240798A1/es unknown
- 2022-09-01 TW TW111133119A patent/TW202320754A/zh unknown
- 2022-09-05 AR ARP220102396A patent/AR126980A1/es unknown
-
2023
- 2023-08-11 US US18/233,031 patent/US11912692B2/en active Active
-
2024
- 2024-02-08 DO DO2024000024A patent/DOP2024000024A/es unknown
- 2024-02-29 JO JOJO/P/2024/0043A patent/JOP20240043A1/ar unknown
- 2024-02-29 CL CL2024000638A patent/CL2024000638A1/es unknown
- 2024-03-01 CO CONC2024/0002668A patent/CO2024002668A2/es unknown
- 2024-03-27 EC ECSENADI202424658A patent/ECSP24024658A/es unknown
- 2024-04-02 ZA ZA2024/02553A patent/ZA202402553B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA66371B1 (fr) | Dérivés de s-alaninate substitués | |
| MA27794A1 (fr) | Dihydroquinazolines substituees a proprietes antivirales | |
| MA28289A1 (fr) | Immunoglobulines | |
| MA30914B1 (fr) | Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques. | |
| MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| MA30041B1 (fr) | Immunoglobulines | |
| EP1133294A4 (fr) | Compositions et methodes de traitement de la maladie d'alzheimer, de lesions du systeme nerveux central et de maladies inflammatoires | |
| MA33123B1 (fr) | 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation | |
| MA43116A (fr) | Ditosylate de valbénazine et polymorphes associés | |
| ZA841373B (en) | Quinolonecarboxylic acids,processes for their preparation and antibacterial agents containing these compounds | |
| MY140488A (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
| BR0317230A (pt) | Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto | |
| MA30462B1 (fr) | Composes de pyridylamide antagonistes des canaux calciques de type t | |
| MA39018A1 (fr) | (aza)pyridopyrazolopyrimidinones et indazolopyrimidinones utilisées comme inhibiteurs de la fibrinolyse | |
| MX2024011254A (es) | Moduladores de nlrp3 | |
| GEAP202316370A (en) | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3] triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide | |
| MA31535B1 (fr) | (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine | |
| WO2022047128A3 (fr) | Procédé de traitement de troubles médiés par le complément provoqués par des bétacoronavirus | |
| MX2023005076A (es) | Inhibidores de interleucina-17. | |
| ES2174921T3 (es) | Inhibidores de la proteasa del vih. | |
| EP4351547A4 (fr) | Composés, compositions et procédés pour la prévention et/ou le traitement de diverses maladies ou troubles mitochondriaux, notamment la maladie de friedreich | |
| MA62148B1 (fr) | Inhibiteur de magl | |
| EP2059503A4 (fr) | Dérivés d'aminopyrazole, leur procédé de préparation, et composition pour la prévention ou le traitement de maladies ischémiques contenant ces dérivés | |
| EP4155383A4 (fr) | Composition pour le traitement de maladies respiratoires ou de maladies inflammatoires provoquées par stimulation par les poussières fines, contenant des bactéries lactiques | |
| MA31902B1 (fr) | Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque |